In PDAC, a mutated KRAS gene is an attractive biomarker since KRAS mutation is observed in >90% PDAC and appears to occur during carcinogenesis28, so that almost all cancer cells within a tumor harbor KRAS mutations. Here, KRAS is linked to neoplasm.